Personalis (NASDAQ:PSNL) Now Covered by Analysts at Guggenheim

Guggenheim initiated coverage on shares of Personalis (NASDAQ:PSNL) in a research report released on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $6.00 price target on the stock.

PSNL has been the topic of several other reports. Craig Hallum began coverage on shares of Personalis in a report on Monday, March 17th. They issued a “buy” rating and a $8.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Personalis in a research report on Thursday, April 10th. Finally, HC Wainwright boosted their price objective on Personalis from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, May 7th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $7.67.

Personalis Price Performance

Personalis stock opened at $4.89 on Thursday. Personalis has a 12-month low of $1.14 and a 12-month high of $7.20. The company has a market capitalization of $431.91 million, a price-to-earnings ratio of -2.91 and a beta of 1.83. The firm’s fifty day moving average price is $3.74 and its 200 day moving average price is $4.47.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The business had revenue of $20.61 million for the quarter, compared to analysts’ expectations of $17.41 million. Analysts forecast that Personalis will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

Institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in Personalis during the 4th quarter worth $28,000. JPMorgan Chase & Co. increased its holdings in shares of Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after acquiring an additional 5,654 shares during the period. Olympiad Research LP bought a new stake in Personalis in the 4th quarter valued at about $59,000. Alpine Global Management LLC bought a new position in Personalis in the 4th quarter worth about $60,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Personalis by 18.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company’s stock valued at $62,000 after purchasing an additional 2,724 shares during the period. 61.91% of the stock is owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.